The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Open accessPublished version of a preprint
Abstract
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. Significance: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Cancer Discov; 6(6); 664–79. ©2016 AACR. See related commentary by Rouce and Heslop, p. 579. This article is highlighted in the In This Issue feature, p. 561
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6–11].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20–25].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Serum biomarkers, including glycoprotein 130 (gp130), interferon-γ, and interleukin-1–receptor antagonist (IL1RA), can be used to predict the severity of cytokine storm induced by CAR T-cell therapy”
From Cytokine storm (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 3×
“In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
BackgroundSelf-citationBorowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Hay, K. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15644 · Cited by 177
CAR T Cell Toxicity: Current Management and Future Directions
Yáñez, L., Sánchez‐Escamilla, M., & Perales, M. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000186 · Cited by 180
Redirecting T cells to hematological malignancies with bispecific antibodies
Velasquez, M. P., Bonifant, C. L., & Gottschalk, S. M. (2017) · Blood · doi:10.1182/blood-2017-06-741058 · Cited by 176
Cao, J., Wang, G., Cheng, H., Wei, C., Qi, K., Sang, W., Li, Z., Shi, M., Li, H., Qiao, J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25108 · Cited by 176
Sandler, R. D., Tattersall, R. S., Schoemans, H. M., Greco, R., Badoglio, M., Labopin, M., Alexander, T., Киргизов, К. И., Rovira, M., Saif, M. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00524 · Cited by 171
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
Abboud, R., Keller, J., Slade, M., DiPersio, J. F., Westervelt, P., Rettig, M. P., Meier, S., Fehniger, T. A., Abboud, C. N., Uy, G. L., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.010 · Cited by 171
Genetic engineering of T cells for immunotherapy
Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 170
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
Jain, M. D., Smith, M. M., & Shah, N. N. (2023) · Blood · doi:10.1182/blood.2022017414 · Cited by 177
Interleukin-6 signalling in health and disease
Rose‐John, S. (2020) · F1000Research · doi:10.12688/f1000research.26058.1 · Cited by 167
Self-citationRyabkova, V. A., Churilov, L. P., & Shoenfeld, Y. (2021) · Clinical Immunology · doi:10.1016/j.clim.2020.108652 · Cited by 164
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Byrd, T. T., Fousek, K., Pignata, A., Szot, C. S., Samaha, H., Seaman, S., Dobrolecki, L. E., Salsman, V. S., Oo, H. Z., Bielamowicz, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1911 · Cited by 164
Sachdeva, M., Duchateau, P. N., Depil, S., Poirot, L., & Valton, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.007558 · Cited by 165
Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines
Roselló, S., Blasco, I., Fabregat, L. G., Cervantes, A. M. R., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx216 · Cited by 163
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 165
Current challenges and emerging opportunities of CAR-T cell therapies
Abreu, T. R., Fonseca, N. A., Gonçalves, N., & Moreira, J. N. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.047 · Cited by 159
Severe cytokine release syndrome in a patient receiving PD‐1‐directed therapy
Rotz, S. J., Leino, D. G., Szabo, S., Mangino, J. L., Turpin, B. K., & Pressey, J. G. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26642 · Cited by 160
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Subklewe, M. S., von Bergwelt‐Baildon, M., & Humpe, A. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000496870 · Cited by 161
Targeting interferon-γ in hyperinflammation: opportunities and challenges
Benedetti, F. D., Prencipe, G., Bracaglia, C., Marasco, E., & Grom, A. A. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00694-z · Cited by 158
Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
Koutsakos, M., Rowntree, L. C., Hensen, L., Chua, B. Y. L., van de Sandt, C. E., Habel, J. R., Zhang, W., Jia, X., Kedzierski, Ł., Ashhurst, T. M., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100208 · Cited by 158
Juluri, K. R., Wu, Q. V., Voutsinas, J. M., Hou, J., Hirayama, A. V. V., Mullane, E., Miles, N., Maloney, D. G., Turtle, C. J., Bar, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004142 · Cited by 159
Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
Singh, N., Hofmann, T. J., Gershenson, Z., Levine, B. L., Grupp, S. A., Teachey, D. T., & Barrett, D. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.04.001 · Cited by 151
Self-citationQu, J., Mei, Q., Chen, L., & Zhou, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02735-0 · Cited by 150
Riegler, L. L., Jones, G. P., & Lee, D. W. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150524 · Cited by 148
Madabhavi, I., Sarkar, M. S., & Kadakol, N. (2020) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2020.1298 · Cited by 146
Bailey, S. R., Vatsa, S., Larson, R. C., Bouffard, A. A., Scarfò, I., Kann, M. C., Berger, T. R., Leick, M. B., Wehrli, M., Schmidts, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0181 · Cited by 158
Liu, H., Lei, W., Zhang, C., Yang, C., Wei, J., Guo, Q., Guo, X., Chen, Z., Lu, Y., Young, K. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1457 · Cited by 147
How I Treat Cytopenias after CAR T-cell Therapy
Jain, T., Olson, T. S., & Locke, F. L. (2023) · Blood · doi:10.1182/blood.2022017415 · Cited by 148
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Wei, J., Liu, Y., Wang, C., Zhang, Y., Tong, C., Dai, G., Wang, W., Rasko, J. E. J., Melenhorst, J. J., Qian, W., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00256-x · Cited by 146
Self-citationEngineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 148
Self-citationCo-Stimulatory Receptor Signaling in CAR-T Cells
Honikel, M. M., & Olejniczak, S. H. (2022) · Biomolecules · doi:10.3390/biom12091303 · Cited by 149
Toxicities of CD19 CAR‐T cell immunotherapy
Hirayama, A. V. V., & Turtle, C. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25445 · Cited by 144
Hay, K. A., & Turtle, C. J. (2017) · Drugs · doi:10.1007/s40265-017-0690-8 · Cited by 144
Pehlivan, K. C., Duncan, B. B., & Lee, D. W. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0470-x · Cited by 142
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Wehrli, M., Gallagher, K., Chen, Y., Leick, M. B., McAfee, S. L., El-Jawahri, A. R., DeFilipp, Z. M., Horick, N., O’Donnell, P. V., Spitzer, T. R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003847 · Cited by 142
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.120.315894 · Cited by 138
Burstein, D. S., Maude, S. L., Grupp, S. A., Griffis, H. M., Rossano, J., & Lin, K. Y. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.05.014 · Cited by 136
Self-citationCytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Obstfeld, A. E., Frey, N. V., Mansfield, K. G., Lacey, S. F., June, C. H., Porter, D. L., Melenhorst, J. J., & Wasik, M. A. (2017) · Blood · doi:10.1182/blood-2017-08-802413 · Cited by 134
Self-citationFoster, J., Choudhari, N., Perazzelli, J., Storm, J., Hofmann, T. J., Jain, P., Storm, P. B., Pardi, N., Weissman, D., Waanders, A. J., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.145 · Cited by 138
Self-citationIn the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy
Borrega, J. G., Gödel, P., Rueger, M. A., Onur, O. A., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000191 · Cited by 140
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
Bonaventura, A., Vecchié, A., Wang, T. S., Lee, E., Cremer, P. C., Carey, B. C., Rajendram, P., Hudock, K. M., Korbee, L. L., Tassell, B. W. V., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01625 · Cited by 137
Topp, M. S., van Meerten, T., Houot, R., Minnema, M. C., Bouabdallah, K. K., Lugtenburg, P. J., Thiéblemont, C., Wermke, M., Song, K., Avivi, I. M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17673 · Cited by 133
Hu, Y., Wu, Z., Luo, Y., Shi, J., Yu, J., Pu, C., Liang, Z., Wei, G., Cui, Q., Sun, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1799 · Cited by 131
COVID-19: In the Eye of the Cytokine Storm
de la Rica, R., Borges-Sa, M., & González‐Freire, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.558898 · Cited by 134
Cosenza, M., Sacchi, S., & Pozzi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147652 · Cited by 134
Ruella, M., Kenderian, S. S., Shestova, O. E., Klichinsky, M., Melenhorst, J. J., Wasik, M. A., Lacey, S. F., June, C. H., & Gill, S. I. (2016) · Leukemia · doi:10.1038/leu.2016.262 · Cited by 132
Self-citationImproving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
Jiang, H., Liu, L., Guo, T., Wu, Y., Ai, L., Deng, J., Dong, J. W., Mei, H., & Hu, Y. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03685-z · Cited by 132
Advancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 130
Gupta, S., Seethapathy, H. S., Strohbehn, I. A., Frigault, M. J., O’Donnell, E., Jacobson, C. A., Motwani, S. S., Parikh, S. M., Curhan, G. C., Reynolds, K. L., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.10.011 · Cited by 127
Reactions Related to CAR-T Cell Therapy
Miao, L., Zhang, Z., Ren, Z., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663201 · Cited by 129
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy
Hines, M., Keenan, C., Marón, G. M., Cheng, C., Zhou, Y., Sharma, A., Hurley, C., Nichols, K. E., Gottschalk, S. M., Triplett, B. M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17662 · Cited by 124
Immunotherapy in pediatric acute lymphoblastic leukemia
Inaba, H., & Pui, C. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09834-0 · Cited by 129
Xu, Y., Yang, Z., Horan, L. H., Zhang, P., Liu, L., Zimdahl, B., Green, S., Lu, J., Morales, J. F., Barrett, D. M., et al. (2018) · Cell Discovery · doi:10.1038/s41421-018-0066-6 · Cited by 126
Self-citationTay, S. H., Toh, M. M. X., Thian, Y. L., Vellayappan, B. A., Fairhurst, A., Chan, Y. H., Aminkeng, F., Bharwani, L. D., Huang, Y., Mak, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807050 · Cited by 122
Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells
Maulana, T. I., Teufel, C., Cipriano, M., Roosz, J., Lazarevski, L., van den Hil, F. E., Scheller, L., Orlova, V. V., Koch, A., Hudecek, M., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.04.018 · Cited by 125
Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma
Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.745320 · Cited by 121
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Titov, A., Petukhov, A., Staliarova, A., Motorin, D., Bulatov, E., Shuvalov, O. Y., Soond, S. M., Piacentini, M., Melino, G., Zaritskey, A. Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0918-x · Cited by 124
Bajor, D. L., Mick, R., Riese, M. J., Huang, A. C., Sullivan, B. J., Richman, L. P., Torigian, D. A., George, S. M., Stelekati, E., Chen, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1468956 · Cited by 123
Self-citationThe growing world of CAR T cell trials: a systematic review
Holzinger, A., Barden, M., & Abken, H. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1895-5 · Cited by 121
Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy
Zhang, Q., Zhu, B., & Li, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00071 · Cited by 121
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
Singh, A. K., Dees, S., & Grewal, I. S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01225-5 · Cited by 118
Kappert, K., Jahić, A., & Tauber, R. (2020) · Biomarkers · doi:10.1080/1354750x.2020.1797880 · Cited by 117
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Lu, L., Xie, M., Yang, B., Zhao, W., & Cao, J. (2024) · Science Advances · doi:10.1126/sciadv.adj6251 · Cited by 122
Neurotoxicity after CTL019 in a pediatric and young adult cohort
Gofshteyn, J. S., Shaw, P. A., Teachey, D. T., Grupp, S. A., Maude, S. L., Banwell, B., Chen, F., Lacey, S. F., Melenhorst, J. J., Edmondson, M. J., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25315 · Cited by 119
Self-citationChimeric Antigen Receptor T-Cell Therapy for Cancer and Heart
Ganatra, S., Carver, J. R., Hayek, S. S., Ky, B., Leja, M. J., Lenihan, D. J., Lenneman, C. G., Mousavi, N., Park, J. H., Perales, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.049 · Cited by 118
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.19 · Cited by 115
Self-citationYang, J., He, J., Zhang, X., Li, J., Wang, Z., Zhang, Y., Qiu, L., Wu, Q., Sun, Z., Ye, X., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00694-6 · Cited by 118
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Pfefferle, A., & Huntington, N. D. (2020) · Cancers · doi:10.3390/cancers12030706 · Cited by 117
Yang, Y. P., Sun, X., Xu, J., Cui, C., Yazd, H. S., Pan, X., Zhu, Y., Chen, X., Li, X., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09884 · Cited by 112
Song, Y., Tong, C., Wang, Y., Gao, Y., Dai, H., Guo, Y., Zhao, X., Wang, Y., Wang, Z., Han, W., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0384-8 · Cited by 112
Vairy, S., Garcia, J. L., Teira, P., & Bittencourt, H. N. D. S. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s138765 · Cited by 112
CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape
Pettitt, D., Arshad, Z., Smith, J. A., Stanic, T., Holländer, G. A., & Brindley, D. A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.019 · Cited by 115
Management of cytokine release syndrome related to CAR-T cell therapy
Chen, H., Wang, F., Zhang, P., Zhang, Y., Chen, Y., Fan, X.-H., Cao, X.-M., Liu, J., Yang, Y., Wang, B., et al. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0714-8 · Cited by 113
The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19
Attiq, A., Yao, L. J., Afzal, S., & Khan, M. A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108255 · Cited by 111
Si, S., & Teachey, D. T. (2020) · PubMed Central · doi:10.2147/tcrm.s223468 · Cited by 108
Self-citationThe Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy
Zhang, S., Chen, W., Zhou, J., Liang, Q., Zhang, Y., Su, M., Zhang, Z., & Qu, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s499403 · Cited by 114
Cytokine-mediated CAR T therapy resistance in AML
Bhagwat, A. S., Torres, L., Shestova, O. E., Shestov, M., Mellors, P. W., Fisher, H. R., Farooki, S., Frost, B. F., Loken, M. R., Gaymon, A. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03271-5 · Cited by 117
Self-citationCytokine release syndrome: Who is at risk and how to treat
Frey, N. V. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.09.002 · Cited by 106
Self-citationThe Pharmacology of T Cell Therapies
Milone, M. C., & Bhoj, V. G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.010 · Cited by 103
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
Brandt, L. J. B., Barnkob, M. B., Michaels, Y. S., Heiselberg, J., & Barington, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00326 · Cited by 105
Macrophage, the potential key mediator in CAR-T related CRS
Hao, Z., Li, R., Li, M., Han, Z., & Hong, Z. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00171-5 · Cited by 107
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia
Temesgen, Z., Assi, M., Shweta, F., Vergidis, P. I., Rizza, S. A., Bauer, P. R., Pickering, B. W., Razonable, R. R., Libertin, C. R., Burger, C. D., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.038 · Cited by 104
The Inflammasome in Times of COVID-19
Vaccari, J. C. D. R., Dietrich, W. D., Keane, R. W., & Vaccari, J. P. D. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583373 · Cited by 104
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells
Haas, A. R., Golden, R. J., Litzky, L. A., Engels, B., Zhao, L., Xu, F., Taraszka, J. A., Ramones, M., Granda, B. W., Chang, W., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.006 · Cited by 103
Self-citationGauthier, J., & Yakoub‐Agha, I. (2017) · Current Research in Translational Medicine · doi:10.1016/j.retram.2017.08.003 · Cited by 107
State of the art in CAR T cell therapy for CD19+ B cell malignancies
Frigault, M. J., & Maus, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129208 · Cited by 107
Shalabi, H., Sachdev, V., Kulshreshtha, A., Cohen, J. W., Yates, B., Rosing, D. R., Sidenko, S., Delbrook, C., Mackall, C. L., Wiley, B. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001159 · Cited by 102
The Roles of Neutrophils in Cytokine Storms
Chan, L., Karimi, N., Morovati, S., Alizadeh, K., Kakish, J. E., Vanderkamp, S., Fazel, F., Napoleoni, C., Alizadeh, K., Mehrani, Y., et al. (2021) · Viruses · doi:10.3390/v13112318 · Cited by 102
Acharya, U. H., Dhawale, T. M., Yun, S., Jacobson, C. A., Chávez, J. C., Ramos, J., Appelbaum, J., & Maloney, D. G. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1585238 · Cited by 102
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
Yoshida, T., Ichikawa, J., Giuroiu, I., Laino, A. S., Hao, Y., Krogsgaard, M., Vassallo, M., Woods, D. M., Hodi, F. S., & Weber, J. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000234 · Cited by 100
Huarte, E., O’Connor, R. S., Peel, M. T., Nuñez-Cruz, S., Leferovich, J. M., Juvekar, A., Yang, Y., Truong, L., Huang, T., Naim, A. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1739 · Cited by 102
The EBMT/EHA CAR-T Cell Handbook
Kröger, N., Gribben, J. G., Chabannon, C., Yakoub‐Agha, I., & Einsele, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0 · Cited by 106
Morris, G., Bortolasci, C. C., Puri, B. K., Marx, W., O'Neil, A. E., Athan, E., Walder, K. R., Berk, M., OLIVE, L. S., Carvalho, A. F., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155593 · Cited by 101
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Min, I. M., Shevlin, E., Vedvyas, Y., Zaman, M., Wyrwas, B., Scognamiglio, T., Moore, M. D., Wang, W., Park, S., Park, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2008 · Cited by 99
Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 103
Engineering chimeric antigen receptor-T cells for cancer treatment
Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95
Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors
Vedvyas, Y., Shevlin, E., Zaman, M., Min, I. M., Amor‐Coarasa, A., Park, S., Park, S., Kwon, K.-W., Smith, T., Luo, Y., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.90064 · Cited by 94
Tang, X.-Y., Sun, Y., Zhang, A., Hu, G., Cao, W. W., Wang, D., Zhang, B., & Chen, H. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-013904 · Cited by 95
Metadata
- Authors
- Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- 10Institute of Biochemistry, CAU Kiel, Germany.
- Alexander T. Augusta Military Medical Center (US)
- Corresponding author
- Teachey, David T.
- ORCID
- Teachey, David T.
- Lacey, Simon F.
- Shaw, Pamela A.
- Melenhorst, J. Joseph
- Maude, Shannon L.
- Frey, Noelle
- Gonzalez, Vanessa E.
- Chen, Fang
- Barrett, David M.
- Weiss, Scott L.
- Fitzgerald, Julie C.
- Berg, Robert A.
- Aplenc, Richard
- Callahan, Colleen
- Rheingold, Susan R.
- Zheng, Zhaohui
- Wertheim, Gerald
- Levine, Bruce L.
- June, Carl H.
- Porter, David L.
- Grupp, Stephan A.
- Venue
- Cancer Discovery
- Published
- 2016-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 664-679
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5448406
- OpenAlex
- W2340435799
- Cited by
- 1,102
- References
- 35
- Citations by year
- 2026: 72 · 2025: 116 · 2024: 94 · 2023: 110 · 2022: 102 · 2021: 142 · 2020: 181 · 2019: 103 · 2018: 93 · 2017: 64 · 2016: 22
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA165206, R01CA102646, R01CA116660, R01CA193776, P30CA016520)
- National Institute of General Medical Sciences (K23GM110496)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cytokine release syndrome, CAR T-cell therapy, acute lymphoblastic leukemia, CD19 CAR T cells, tisagenlecleucel, predictive biomarkers, cytokine profiling, interferon-gamma, interleukin-6, soluble gp130, C-reactive protein, ferritin, relapsed/refractory leukemia, toxicity prediction
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunotherapy, Male, Middle Aged, Phenotype, Prognosis, Receptors, Antigen, T-Cell, ROC Curve, Severity of Illness Index, Tumor Lysis Syndrome, Biomarkers, Cytokines, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
